The majority of FDA-approved biology-derived products are recombinant glycoproteins. These proteins have been used for the treatment of several diseases, with numerous products currently approved for clinical use. The choice of the expression system is a key step toward a successful functional protein production, since glycosylation influences yield, pharmacokinetics, biological activity, and immunogenicity. This chapter covers the general aspects of therapeutic recombinant glycoproteins and the platforms that are being employed for their production.
CITATION STYLE
Mizukami, A., Caron, A. L., Picanço-Castro, V., & Swiech, K. (2018). Platforms for recombinant therapeutic glycoprotein production. In Methods in Molecular Biology (Vol. 1674, pp. 1–14). Humana Press Inc. https://doi.org/10.1007/978-1-4939-7312-5_1
Mendeley helps you to discover research relevant for your work.